A little dose goes a long way.
CaPP3’s results show that taking as little as 75 to 100mg of aspirin each day can halve the risk of bowel cancer in people with Lynch syndrome, a heritable genetic condition that makes bowel cancer much more likely. The findings mean regulators and doctors should soon be able to recommend a specific low-dose aspirin prescription for people with Lynch syndrome, protecting many more of them from bowel cancer.
Below you’ll find short summaries of each talk, with a link to the YouTube recordings on our YouTube channel, as well as links to additional useful resources at the end.
https://www.lynch-syndrome-uk.org/post/lynch-syndrome-conference-2025-highlights
Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome. The choice of extended or partial colectomy in patients with LS with primary CRC may influence the risk of metachronous CRC. This study aimed to identify factors associated with metachronous CRC risk and evaluate their potential implications for surgical decision-making.
Metachronous (CRC) is a new, separate primary cancer of the colorectum that develops after a patient has already been diagnosed with and treated for an initial CRC.
This study identifies important risk factors for metachronous CRC in patients with LS, which may support personalised counseling regarding surgical strategies. The findings highlight the complexity of surgical decision-making and the need for individualised approaches. Further studies are required to refine risk stratification and evaluate long-term outcomes to optimise patient care.
https://www.cghjournal.org/article/S1542-3565(25)00638-X/fulltext
Check out their newly launched version….lots of information that you might find useful.
The faecal immunochemical test (FIT) is a diagnostic triage tool for patients presenting with clinical features of CRC in primary care, though its performance in individuals under 50 years is not well established.
Conclusions: FIT performs excellently for patients aged 40-49; however, it may not be used optimally in patients <40 years. A more targeted strategy is needed to guide investigation in younger patients.
A prospective Lynch syndrome database is important because it allows researchers, clinicians, and policymakers to collect and analyse long-term, standardised data on people with Lynch syndrome (LS).
(Using Chat GPT)
📌 In short: A prospective Lynch syndrome database is essential because it produces high-quality, unbiased evidence on cancer risks, surveillance effectiveness, and preventive strategies, directly improving patient care and shaping clinical guidelines.
Here are the key reasons why it matters, based only on reliable clinical and research perspectives:
Patients, Bowels, Basics, and Breakthroughs
On 11th & 12th September, RSCI is holding a bowel cancer event dedicated to patients, families, and the wider community affected by this cancer.
PVCR Chair Prof Amanda McCann is leading a session on Friday 12th September at 1:30pm on “The Importance of PPI in Research” with PhD students from ColoMARK and patient advocates from Bowel Cancer Ireland.
There will also be open conversations with doctors, researchers, and experts in fertility, sexual health, and psycho-oncology across the two days.
You can click here or scan the QR code below to register. Any questions or concerns can be directed to EpiGastroDRG@outlook.com
You can also check out their free bowel cancer informational booklet here or through the QR code below to the right.
A recent survey reveals the extent of the issue: 75% of EOCRC patients saw at least two doctors before receiving a diagnosis, and 20% saw four or more. These delays, often driven by medical bias, can be life-altering.
Colonoscopy is expected to reduce colorectal cancer (CRC) incidence in Lynch syndrome (LS) by detecting and removing adenomas. The existence of gene-specific differences in adenoma detection has been proposed yet remains insufficiently explored.
Carriers of MLH1/MSH2 pathogenic variants are at a higher risk of developing AAs compared with those with MSH6/PMS2 mutations, with MSH6 carriers exhibiting an intermediate risk profile. Advanced adenomas(AA) are an independent risk factor for post-colonoscopy CRC . LS patients with AAs should be identified as high risk and undergo enhanced colonoscopy surveillance.
https://www.sciencedirect.com/science/article/abs/pii/S001650852500650X?dgcid=author
Be Your Own Advocate
Build your colorectal cancer treatment team: -You, of course, are the starring player.
Make sure you have an overall care coordinator.
Lynch Syndrome Ireland 